- Home
- TLPH
TLPH
Talphera Inc.
as 06-23-2025 4:00pm EST
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.
| Founded: | 2005 | Country: | United States |
| Employees: | N/A | City: | SAN MATEO |
| Market Cap: | 10.6M | IPO Year: | 2011 |
| Target Price: | $6.00 | AVG Volume (30 days): | 31.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.44 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.44 - $1.19 | Next Earning Date: | 08-13-2025 |
| Revenue: | $27,000 | Revenue Growth: | -95.85% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 14533.26% |
Stock Insider Trading Activity of Talphera Inc. (TLPH)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Angotti Vincent J. | TLPH | CHIEF EXECUTIVE OFFICER | Apr 2 '25 | Buy | $0.59 | 213,310 | $124,999.66 | 403,769 |
Latest Talphera Inc. News
TLPH Breaking Stock News: Dive into TLPH Ticker-Specific Updates for Smart Investing
GuruFocus.com
a month ago
Talphera Inc (TLPH) Q1 2025 Earnings Call Highlights: Strategic Cost Reductions and FDA ...
PR Newswire
a month ago
Talphera Announces First Quarter 2025 Financial Results and Provides Corporate Update
PR Newswire
2 months ago
Talphera to Host First Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, May 14, 2025
Argus Research
3 months ago
Daily – Vickers Top Buyers & Sellers for 04/04/2025
GuruFocus.com
3 months ago
Talphera Inc (TLPH) Q4 2024 Earnings Call Highlights: Strategic Moves and Financial Insights
PR Newswire
3 months ago
Talphera Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
PR Newswire
3 months ago
Talphera Announces Agreement with the FDA to Reduce the NEPHRO CRRT Study Size to 70 Patients From 166 and a Private Placement Financing Priced At-the Market of up to $14.8 Million
PR Newswire
3 months ago
Talphera to Host Fourth Quarter and Full-Year 2024 Financial Results and Corporate Update Call and Webcast on Monday, March 31, 2025
Compare TLPH vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TLPH Talphera Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.